Towards a new age of virtual ADME/TOX and multidimensional drug discovery

Journal of Computer-Aided Molecular Design

Volumn 16, Issue 5-6, 2002, Pages 381-401

  Ekins, Sean ^a   Boulanger, Bruno ^b   Swaan, Peter W ^c   Hupcey, Maggie A Z ^a  

^a 19034   (United States)

^b Eli Lilly Benelux   (Belgium)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG INTERACTIONS; MOLECULES; SYNTHESIS (CHEMICAL); TOXICITY;

ABSORPTION DISTRIBUTION; BLOCKBUSTER DRUGS; DRUG DISCOVERY; FOLLOW UP; NEW AGE; PHARMACEUTICAL COMPANY; PROPERTY; RESEARCH PROCESS; SYNTHESIZED MOLECULES; TOXICITY DATA;

METABOLISM;

ACEBUTOLOL; ACICLOVIR; ATENOLOL; BACTERIORHODOPSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARRIER PROTEIN; CARTEOLOL; CYTOCHROME P450; CYTOCHROME P450 2B; CYTOCHROME P450 3A4; DRUG; ENVIROXIME; ENZYME; GLUCOSE TRANSPORTER; LABETALOL; METOPROLOL; NADOLOL; PINDOLOL; POLYMER; PREGNANE X RECEPTOR; PRODRUG; PROPRANOLOL; SEROTONIN; SOTALOL; SULFONAMIDE; SULFONYLUREA; TIMOLOL; UNINDEXED DRUG; VALACICLOVIR;

ANIMAL CELL; BLOOD BRAIN BARRIER; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG ACTIVITY; DRUG COST; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG INTERACTION; DRUG MARKETING; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; DRUG TRANSPORT; ENZYME INDUCTION; HUMAN; IN VITRO STUDY; INTESTINE ABSORPTION; NONBIOLOGICAL MODEL; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAT; REVIEW; ARTICLE; BIOAVAILABILITY; DRUG INDUSTRY; PHARMACOKINETICS; TOXICITY TESTING;

BIOLOGICAL AVAILABILITY; DRUG DESIGN; DRUG INDUSTRY; HUMANS; PHARMACOKINETICS; TOXICITY TESTS;

EID: 0036589360     PISSN: 0920654X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020816005910     Document Type: Review

References (124)

1. Love, B., PSTT, 1 (1998) 89-90.
2. Cavalla, D., PSTT, 1 (1998) 91-92.
3. Kennedy, T., Drug Discovery Today, 2 (1997) 436-444.
4. Lipinski, C.A., Lombardo, F., Dominy, B.W. and Feeney, P.J., Adv. Drug. Del. Rev. 23 (1997) 3-25.
5. Lipinski, C.A., J. Pharm. Toxicol. Methods, 44 (2000) 235-249.
6. Lipinski, C.A., Curt. Drug Discovery, April (2001) 17-19.
7. Gillet, V.J., Willett, P. and Bradshaw, J., J. Chem. Inf. Comp. Sci., 38 (1998) 165-179.
8. Sadowski, J. and Kubinyi, H., J. Med. Chem., 41 (1998) 3325-3329.
9. Oprea, T.I., Davis, A.M., Teague, S.J. and Leeson, P.D., J. Chem. Inf. Comput. Sci., 41 (2001) 1308-1315.
10. Bemis, G.W. and Murcko, M.A., J. Med. Chem., 39 (1996) 2887-2893.
11. Bemis, G.W. and Murcko, M.A., J. Med. Chem., 42 (1999) 5095-5099.
12. Muegge, I., Heald, S.L. and Brittelli, D., J. Med. Chem., 44 (2001) 1-6.
13. Ekins, S., Ring, B.J., Bravi, G., Wikel, J.H. and Wrighton, S.A., (2000b) Predicting drug-drug interactions in silico using pharmacophores: A paradigm for the next millenium, in Pharmacophore, perception, development, and use in drug design (Guner OF ed) 269-299, University International Line, San Diego.
14. Ekins, S., Waller, C.L., Swaan, P.W., Cruciani, G., Wrighton, S.A. and Wikel, J.H., J. Pharm. Tox. Methods, 44 (2000d) 251-272.
15. Barratt, M.D., Env. Health. Perspectives., 106 (1998) 459-465.
16. Ekins, S., Ring, B.J., Grace, J., McRobie-Belle, D.J. and Wrighton, S.A., J. Pharm. Tox. Methods, 44 (2000c) 313-324.
17. Barratt, M.D. and Rodford, R.A., Curr. Opin. Chem. Biol., 5 (2001) 383-388.
18. Lombardo, F., Blake, J.F. and Curatolo, W.J., J. Med. Chem. 39 (1996) 4750-4755.
19. Ekins, S., Durst, G.L., Stratford, R.E., Thorner, D.A., Lewis, R., Loncharich, R.J. and Wikel, J.H., J. Chem. Inf. Comput. Sci., 41 (2001b) 1578-1586.
20. Stenberg, P., Norinder, U., Luthman, K. and Artursson, P., J. Med. Chem., 44 (2001) 1927-1937.
21. Walters, W.P., Stahl, M.T. and Murcko, M.A., Drug Discovery Today, 3 (1998) 160-178.
22. Leach, A.R. and Hann, M.M., Drug Discovery Today, 5 (2000) 326-336.
23. Barnum, D., Greene, J., Smellie, A. and Sprague, P., J. Chem. Inf. Comput. Sci. 36 (1996) 563-571.
24. Ekins, S., Bravi, G., Wikel, J.H. and Wrighton, S.A., J. Pharmacol. Exp. Ther., 291 (1999d) 424-433.
25. Chen, X., Rusinko, I., Tropsha, A. and Young, S.S., J. Chem. Inf. Comput. Sci., 39 (1999) 887-896.
26. Saiakhov, R., Stefan, L.R. and Klopman, G., Persp. Drug. Disc. Design., 19 (2000) 133-135.
27. Colmenarejo, G., Alvarez-Pedraglio, A. and Lavandera, J.L., J. Med. Chem., 44 (2001) 4370-4378.
28. Crumb, Jr. W.J., Ekins, S., Sarazan, D., Wikel, J.H., Wrighton, S.A., Carlson, C. and Beasley, C., J. Clin. Psychiatry., (2002) in press.
29. Ekins, S., Crumb, W.J., Sarazan, R.D., Wikel, J.H. and Wrighton, S.A., J. Pharmacol. Exp. Ther., (2002) in press.
30. Manly, C.J., Louise-May, S. and Hammer, J.D., Drug Discovery Today, 6 (2001) 1101-1110.
31. Ekins, S., Bravi, G., Binkley, S., Gillespie, J.S., Ring, B.J., Wikel, J.H. and Wrighton, S.A., J. Pharmacol. Exp. Ther., 290 (1999b) 429-438.
32. Ekins, S., Bravi, G., Binkley, S., Gillespie, J.S., Ring, B.J., Wikel, J.H. and Wrighton, S.A., Pharmacogenetics, 9 (1999a) 477-489.
33. Ekins, S., Bravi, G., Binkley, S., Gillespie, J.S., Ring, B.J., Wikel, J.H. and Wrighton, S.A., Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors, 28 (2000a) 994-1002.
34. Ekins, S., de Groot, M. and Jones, J.P., Drug. Metab. Dispos., 29 (2001a) 936-944.
35. Bertz, R.J. and Granneman, R.G., Clin. Pharmacokinet., 32 (1997) 210-258.
36. Destroyer, A., Vander Heyden, Y., Carda-Broch, S., Garcia-Alvarez-Coque, M.C. and Massart, D.L. J. Chromatogr. A., 912 (2001) 211-221.
37. van de Waterbeemd, H., Smith, D.A. and Jones, B.C., J. Comput.-Aid. Mol. Des., 15 (2001) 273-286.
38. Stratford, R.E.J., Clay, M.P., Heinz, B.A., Kuhlfeld, M.T., Osborne, S.J., Phillips, D.L., Sweetan, S.A., Tebbe, M.J., Vasudevan, V., Zornes, L.L. and Lindstrom, T.D., J. Pharm. Sci., 88 (1999) 747-753.
39. Palm, K., Stenberg, P., Luthman, K. and Artursson, P., Pharm. Res., 14 (1997) 568-571.
40. Yazdanian, M., Glynn, S.L., Wright, J.L. and Hawi, A., Pharm. Res., 15 (1998) 1490-1494.
41. Palm, K., Luthman, K., Ungell, A.-L., Strandlund, G. and Artursson, P., J. Pharm. Sci., 85 (1996) 32-39.
42. Palm, K., Luthman, K., Ungell, A.-L., Strandlund, G., Beigi, F., Lundahl, P. and Artursson, P, J. Med. Chem., 41 (1998) 5382-5392.
43. Clark, D.E., J. Pharm. Sci., 88 (1999) 807-814.
44. Stenberg, P., Luthman, K., Ellens, H., Lee, C.P., Smith, P.L., Lago, A., Elliot, J.D. and Artursson, P., Pharm. Res., 16 (1999) 1520-1526.
45. Stenberg, P, Luthman, K. and Artursson, P., J. Control. Rel., 65 (2000) 231-243.
46. Ren, S. and Lien, E.J., Prog. Drug. Res., 54 (2000) 1-23.
47. Egan, W.J., Merz, K.M.J. and Baldwin, J.J., J. Med. Chem., 43 (2000) 3867-3877.
48. Schipper, N.G.M., Osterberg, T., Wrange, U., Westberg, C., Sokolowski, A., Rai, R., Young, W. and Sjostrom, B., Pharm. Res., 18 (2001) 1735-1741.
49. Oprea, T.I. and Gottfries, J., J. Mol. Graph. Model., 17 (1999) 261-274.
50. Ghuloum, A.M., Sage, C.R. and Jain, A.N., J. Med. Chem., 42 (1999) 1739-1748.
51. Andrews, C.W., Bennett, L. and Yu, L.X., Pharm. Res., 17 (2000) 639-644.
52. van de Waterbeemd, H., Camenenisch, G., Golkers, G. and Raevsky, O.A., QSAR, 15 (1996) 480-490.
53. Yoshida, F. and Topliss, J.G., J. Med. Chem., 43 (2000) 2575-2585.
54. Derringer, G. and Suich, R., J. Quality Technology, 12 (1980) 214-219.
55. Rassokin, D.N. and Agrafiotis, D.K., J. Mol. Graph. Model., 18 (2000) 368-382.
56. Agratiotis, D.K., J. Chem. Inf. Comput. Sci., 41 (2002) 159-167.
57. Wrighton, S.A., Schuetz, E.G., Thummel, K.E., Shen, D.D., Korzekwa, K.R. and Watkins, P.B., Drug. Metab. Revs., 32 (2000) 339-361.
58. Gao, F., Johnson, D.L., Ekins, S., Janiszewski, J., K.G. K., Meyer, R.D. and West, M., (2001) Submitted.
59. Bursi, R., de Gooyer, M.E., Grootenhuis, A., Jacobs, P.L., van der Louw, J. and Leysen, D., J. Mol. Graph. Modelling., 19 (2001) 552-556.
60. Ekins, S. and Rose, J.P., J. Mol. Graph., 20 (2002) 305-309.
61. Lave, T., Dupin, S., Schmitt, C., Valles, B., Ubeaud, G., Chou, R,C., Jaeck, D. and Coassolo, P., Pharm. Res. 14 (1997) 152-155.
62. Schneider, G., Coassolo, P. and Lave, T., J. Med. Chem., 42 (1999) 5072-5076.
63. Ekins, S. and Obach, R.S., J. Pharmacol. Exp. Ther., 295 (2000) 463-473.
64. Quinones, C., Caceres, J., Stud, M. and Martinez, A., Quant Struct Act Rel., 19 (2000) 448-454.
65. Hansch, C., Drug Metabolism Reviews, 15 (1984) 1279-1294.
66. Cronin, M.T., Pharm. Pharmacol. Commun., 4 (1998) 157-163.
67. Richard, A.M., Toxicol. Lett., 102-103 (1998) 611-616.
68. Johnson, D.E. and Wolfgang, G.H.I., DDT, 5 (2000) 445-454.
69. Smith, C.J., Hansch, C. and Morton, M.J., Mutation Res., 379 (1997) 167-175.
70. Benigni, R., Passerini, L., Gallo, G., Giorgi, F. and Cotta-Ramusino, M., Env. Mol. Mutagenesis., 32 (1998) 75-83.
71. Mathews, E.J. and Contrera, J.F., Reg. Toxicol Pharmacol, 28 (1998) 242-264.
72. Tafozoli, M., Baeten, A., Geerlings, P. and Kirsch-Volders, M., Mutagenesis, 13 (1998) 115-126.
73. Llorens, O., Perez, J.J. and Villar, H.O., J. Med. Chem., 44 (2001) 2793-2804.
74. Stoffers, A.E.M.F., Boersma, M.G., Vaes, W.H.J., Vervoort, J., Tyrakowska, B., Hermens, J.L.M. and Rietjens, I.M.C.M., Toxicol in vitro, 15 (2001) 539-551.
75. Guilhermino, L., Diamantino, T., Silva, M.C. and Soares, A.M.V.M., Ecotoxicol Env. Safety, 46 (2000) 357-362.
76. Calleja, M.C., Persoone, G. and Geladi, P., Fd. Chem. Toxic., 32 (1994) 173-187.
77. Briens, E, Bureau, R. and Rault, S., Ecotxicol. Env. Safety., 43 (1999) 241-251.
78. Cronin, M.T.D. and Schultz, T.W., Chem. Res. Toxicol., 14 (2001) 1284-1295.
79. Kulkarni, A.S. and Hopfinger, A.J., Pharm. Res., 16 (1999) 1245-1253.
80. Patlewicz, G.Y., Rodford, R.A., Ellis, G. and Barratt, M.D., Toxicol in vitro, 14 (2000) 79-84.
81. Rekka, E.A. and Kourounakis, P.N., Eur. J. Drug Metab. Pharmacokinetics, 21 (1996) 7-11.
82. van der Burght, A.S.A.M., Clijsters, P.J., Horbach, G.J., Andersson, P.L., Tysklind, M. and van den Berg, M., Toxicol Appl. Pharmacol., 155 (1999) 13-23.
83. Schuetz, E.G., Beck, W.T. and Schuetz, J.D., Mol. Pharmacol., 49 (1996) 311-318.
84. Watkins, R.E., Wisely, G.B., Moore, L.B., Collins, J.L., Lambert, M.H., Williams, S.P., Willson, T.M., Kliewer, S.A. and Redinbo, M.R., Science, 292 (2001) 2329-2333.
85. Ekins, S. and Erickson, J.A., Drug. Metab. Dispos., 30 (2002) 96-99.
86. Ekins, S. and Schuetz, E., TIPS, (2002).
87. Honkakoski, P., Zelko, I., Sueyoshi, T. and Negishi, M., Mol. Cell. Biol., 18 (1998) 5652-5658.
88. Honkakoski, P., Jaaskelainen, I., Kortelahti, M. and Urtti, A., Pharm. Res. 18 (2001) 146-150.
89. Ekins, S., Bravi, G., Ring, B.J., Gillespie, T.A., Gillespie, J.S., VandenBranden, M., Wrighton, S.A. and Wikel, J.H., J. Pharmacol. Exp. Ther., 288 (1999c) 21-29.
90. Forman, B.M., Tzameli, I., Choi, H.-S., Chen, J., Simha, D., Seol, W., Evans, R.M. and Moore, D.D., Nature, 395 (1998) 612-614.
91. Bohm, H.-J. and Klebe, G., Angew. Chem. Int. Ed. Engl., 35 (1996) 2588-2614.
92. So, S.-S. and Karplus, M., J. Comput.-Aid. Mol. Des., 13 (1999) 243-258.
93. Shimada, J., Ishchenko, A.V. and Shakhnovich, E.I., Protein Sci., 9 (2000) 765-775.
94. Deisenhofer, J. and Michel, H., Annu. Rev. Biophys. Chem., 20 (1991a) 247-266.
95. Deisenhofer, J. and Michel, H., Annu. Rev. Cell. Biol., 7 (1991b) 1-23.
96. Unwin, N., Nature, 373 (1995) 37-43.
97. Tsukihara, T., Aoyama, H., Yamashita, E., Tomizaki, T., Yamaguchi, H., Shinzawa-Itoh, K., Nakashima, R., Yaono, R. and Yoshikawa, S., Science, 272 (1996) 1136-1144.
98. Chang, G. and Roth, C.B. Science, 293 (2001) 1793-1800.
99. Goswitz, V.C. and Brooker, R.J., Protein. Sci., 4 (1995) 534-537.
100. Kaback, H.R., Voss, J. and Wu, J., Curt. Opin. Struct. Biol., 7 (1997) 537-542.
101. Varela, M.F. and Wilson, T.H., Biochim. Biophys. Acta, 1276 (1996) 21-34.
102. Doolittle, R.F., Johnson, M.S., Husain, I., Van Houten, B., Thomas, D.C. and Sancar, A., Nature, 323 (1986) 451-453.
103. Baringhaus, K.H., Matter, H., Stenglin, S. and Kramer, W., J. Lipid Res., 40 (1999) 2158-2168.
104. Swaan, P.W., Szoka, F.C.J. and Oie, S., J. Comput. Aid. Mol. Des., 11 (1997) 581-588.
105. Zhang, E.H., Phelps, M.A., Helsper, F. and Swaan, P.W., (2002) submitted.
106. Zuniga, F.A., Shi, G., Haller, J.F., Rubashkin, A., Flynn, D.R., Iserovich, P. and Fischbarg, J., J. Biol. Chem., 276 (2001) 44970-44975.
107. Balimane, P.V., Tamai, I, Guo, A., Nakanishi, T., Kitada, H., Leibach, F.H., Tsuji, A. and Sinko, P.J., Biochem. Biophys. Res. Commun. 250 (1998) 246-251.
108. Han, H., de Vrueh, R.L., Rhie, J.K., Covitz, K.M., Smith, P.L., Lee, C.P., Oh, D.M., Sadee, W. and Amidon, G.L., Pharm. Res., 15 (1998) 1154-1159.
109. Palsson, B., Nature Biotechnology, 18 (2000) 1147-1150.
110. Ekins, S. and McGowan, R.J., Phil. Sci., 9 (2001) 1-23.
111. Pevzner, P.A., (2000) Computational molecular biology. MIT Press, Cambridge, MA.
112. Gerrard, J.A., Sparrow, A.D. and Wells, J.A., Trends Biochem Sci., 26 (2001) 137-140.
113. Wrighton, S.A. and Stevens, J.C., Crit. Rev. Toxicol., 22 (1992) 1-21.
114. Rendic, S. and Di Carlo, F.J., Drug Metab. Rev., 29 (1997) 413-580.
115. Ellis, L.B.M., Speedie, S.M. and McLeish, R., Bioinformatics, 14 (1998) 803-806.
116. Bower, J.M. and Bolouri, H., Computational modeling of genetic and biochemical networks. (2001) The MIT press, Cambridge, MA.
117. Dorner, D., (1996) The logic of failure. Perseus Books, Reading, MA.
118. Baxter, D.A., Canavier, C.C., Clark, Jr. J.W. and Byrne, J.H., J. Neurophysiol., 82 (1999) 2914-2935.
119. Cook, D.L. and Atkins, W.M., Biochemistry, 36 (1997) 10802-10806.
120. Noble, D. and Colatsky, T.J., Emerg. Ther. Targets, 4 (2000) 39-49.
121. Gifford, D.K., Science, 293 (2001) 2049-2051.
122. Darvas, F., Dorman, G. and Papp, A., J. Chem. Inf. Comput. Sci., 40 (2000) 314-322.
123. Ekins, S. and Wrighton, S.A., J. Pharm. Tox. Methods, 44 (2001) 1-5.
124. Hall, A.H., Toxicol. Lett., 102-103 (1998) 623-626.